[Bronchopulmonary aspergillosis: new developments].
Bronchopulmonary aspergillosis are in the news. Invasive pulmonary aspergillosis raise early diagnostic problems and prevention problems in immunocompromised patients. These infections are no unusual in chronic obstructive pulmonary disease. The diagnosis between aspergilloma and chronic necrotizing pulmonary aspergillosis can be difficult. In allergic bronchopulmonary aspergillosis, epidemiology and therapy are questionable. Real progress has been made due to thoracic computed tomographic scan and mycological methods. Better use of amphotericin B, of amphotericin B lipid formulations and of azole antifungal agents, combined with surgical resection if necessary should improve aspergillosis prognosis.
Germaud
P
P
Service de Pneumologie, CHRU Nantes, Hôpital G. et R. Laënnec, 44093 Nantes Cedex.
Renaudin
K
K
Danner
I
I
Morin
O
O
De Lajartre
A Y
AY
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D003937:Diagnosis, Differential; D006801:Humans; D009336:Necrosis; D011379:Prognosis; D014057:Tomography, X-Ray Computed
D000935:Antifungal Agents; D000666:Amphotericin B